Psychopharmacology

, Volume 220, Issue 3, pp 559–564 | Cite as

Depot naltrexone decreases rewarding properties of sugar in patients with opioid dependence

  • Daniel D. Langleben
  • Elliot L. Busch
  • Charles P. O’Brien
  • Igor Elman
Original Investigation

Abstract

Background

Opioid neurotransmission mediates hedonic value of sweet tastants; their intake may be exaggerated by the consumption of exogenous opioids (e.g., opioid dependence). Sweet Taste Test (STT) is a validated quantitative instrument assessing taste perception and hedonic features of sugar (sucrose) using a randomized and double-blind administration at five different sucrose concentrations ranging from 0.05 to 0.83 M.

Methods

The STT and cue-induced craving procedure were administered to opioid-dependent patients (n = 15) before and 1 week after the injection of a long-acting depot naltrexone (XRNT) preparation.

Results

Analyses of covariance, employing sucrose concentration and its perceived taste as covariates, showed that XRNT therapy significantly reduced the self-reported hedonic and motivational characteristics of sucrose. Greater reductions in both these characteristics were associated with more diminution in the cue-induced opioid craving.

Conclusions

Opioid antagonism in opioid-dependent subjects leads to a smaller sweet taste reward, which, in turn, may be proportional to decreased opioid craving. These pilot results support the heuristic value of the STT as a potential marker of the XRNT treatment response and call for further inquiry into potential clinical applications of the test.

Keywords

Naltrexone Glucose Sucrose Opioid Antagonist Reward Motivation Hedonic Sweet taste test Craving Incentive sensitization 

References

  1. Arbisi PA, Billington CJ, Levine AS (1999) The effect of naltrexone on taste detection and recognition threshold. Appetite 32:241–249PubMedCrossRefGoogle Scholar
  2. Berridge KC (2007) The debate over dopamine's role in reward: the case for incentive salience. Psychopharmacology (Berl) 191:391–431CrossRefGoogle Scholar
  3. Berridge KC, Robinson TE (2003) Parsing reward. Trends Neurosci 26:507–513PubMedCrossRefGoogle Scholar
  4. Berridge KC, Robinson TE, Aldridge JW (2009) Dissecting components of reward: ‘liking’, ‘wanting’, and learning. Curr Opin Pharmacol 9:65–73PubMedCrossRefGoogle Scholar
  5. Berthoud HR (2003) Neural systems controlling food intake and energy balance in the modern world. Curr Opin Clin Nutr Metab Care 6:615–620PubMedCrossRefGoogle Scholar
  6. Carr KD (2002) Augmentation of drug reward by chronic food restriction: behavioral evidence and underlying mechanisms. Physiol Behav 76:353–364PubMedCrossRefGoogle Scholar
  7. Childress AR, McLellan AT, O'Brien CP (1986) Abstinent opiate abusers exhibit conditioned craving, conditioned withdrawal and reductions in both through extinction. Br J Addict 81:655–660PubMedCrossRefGoogle Scholar
  8. Childress AR, Mozley PD, McElgin W, Fitzgerald J, Reivich M, O'Brien CP (1999) Limbic activation during cue-induced cocaine craving. Am J Psychiatry 156:11–18PubMedGoogle Scholar
  9. Cicero TJ, Ennis T, Ogden J, Meyer ER (2000) Gender differences in the reinforcing properties of morphine. Pharmacol Biochem Behav 65:91–96PubMedCrossRefGoogle Scholar
  10. Cicero TJ, Aylward SC, Meyer ER (2003) Gender differences in the intravenous self-administration of mu opiate agonists. Pharmacol Biochem Behav 74:541–549PubMedCrossRefGoogle Scholar
  11. Cornish JW, Metzger D, Woody GE, Wilson D, McLellan AT, Vandergrift B, O'Brien CP (1997) Naltrexone pharmacotherapy for opioid dependent federal probationers. J Subst Abuse Treat 14:529–534PubMedCrossRefGoogle Scholar
  12. de Vos JW, Geerlings PJ, van den Brink W, Ufkes JG, van Wilgenburg H (1995) Pharmacokinetics of methadone and its primary metabolite in 20 opiate addicts. Eur J Clin Pharmacol 48:361–366PubMedCrossRefGoogle Scholar
  13. Elman I, Karlsgodt KH, Gastfriend DR, Chabris CF, Breiter HC (2002) Cocaine-primed craving and its relationship to depressive symptomatology in individuals with cocaine dependence. J Psychopharmacol 16(2):163–167Google Scholar
  14. Elman I, Ariely D, Mazar N, Aharon I, Lasko NB, Macklin ML, Orr SP, Lukas SE, Pitman RK (2005) Probing reward function in post-traumatic stress disorder with beautiful facial images. Psychiatry Res 135:179–183PubMedCrossRefGoogle Scholar
  15. Elman I, Borsook D, Lukas SE (2006) Food intake and reward mechanisms in patients with schizophrenia: implications for metabolic disturbances and treatment with second-generation antipsychotic agents. Neuropsychopharmacology 31:2091–2120PubMedCrossRefGoogle Scholar
  16. Fattore L, Altea S, Fratta W (2008) Sex differences in drug addiction: a review of animal and human studies. Womens Health (Lond Engl) 4:51–65CrossRefGoogle Scholar
  17. First M (2002) Diagnostic and statistical manual of mental disorders. Text revision, 4th edn. American Psychiatric Association, WashingtonGoogle Scholar
  18. Garbutt JC, Osborne M, Gallop R, Barkenbus J, Grace K, Cody M, Flannery B, Kampov-Polevoy AB (2009) Sweet liking phenotype, alcohol craving and response to naltrexone treatment in alcohol dependence. Alcohol Alcohol 44:293–300PubMedGoogle Scholar
  19. Grella CE, Lovinger K (2011) 30-year trajectories of heroin and other drug use among men and women sampled from methadone treatment in California. Drug and Alcohol Depend. doi:10.1016/j.drugalcdep.2011.04.004
  20. Grigson PS (2002) Like drugs for chocolate: separate rewards modulated by common mechanisms? Physiol Behav 76:389–395PubMedCrossRefGoogle Scholar
  21. Hillemacher T, Heberlein A, Muschler MA, Bleich S, Frieling H (2011) Opioid modulators for alcohol dependence. Expert Opin Investig Drugs 20(8):1073–1086PubMedCrossRefGoogle Scholar
  22. Hulse GK, Morris N, Arnold-Reed D, Tait RJ (2009) Improving clinical outcomes in treating heroin dependence: randomized, controlled trial of oral or implant naltrexone. Arch Gen Psychiatry 66:1108–1115PubMedCrossRefGoogle Scholar
  23. Kampov-Polevoy A, Garbutt JC, Janowsky D (1997) Evidence of preference for a high-concentration sucrose solution in alcoholic men. Am J Psychiatry 154:269–270PubMedGoogle Scholar
  24. Kampov-Polevoy AB, Eick C, Boland G, Khalitov E, Crews FT (2004) Sweet liking, novelty seeking, and gender predict alcoholic status. Alcohol Clin Exp Res 28:1291–1298PubMedCrossRefGoogle Scholar
  25. Kelley AE, Bakshi VP, Haber SN, Steininger TL, Will MJ, Zhang M (2002) Opioid modulation of taste hedonics within the ventral striatum. Physiol Behav 76:365–377PubMedCrossRefGoogle Scholar
  26. Kelly SM, Schwartz RP, O'Grady KE, Mitchell SG, Reisinger HS, Peterson JA, Agar MH, Brown BS (2009) Gender differences among in- and out-of-treatment opioid-addicted individuals. Am J Drug Alcohol Abuse 35:38–42PubMedCrossRefGoogle Scholar
  27. King A, Cao D, Vanier C, Wilcox T (2009) Naltrexone decreases heavy drinking rates in smoking cessation treatment: an exploratory study. Alcohol Clin Exp Res 33:1044–1050PubMedCrossRefGoogle Scholar
  28. Krupitsky EM, Blokhina EA (2010) Long-acting depot formulations of naltrexone for heroin dependence: a review. Curr Opin Psychiatry 23(3):210–214PubMedCrossRefGoogle Scholar
  29. Laaksonen E, Lahti J, Sinclair JD, Heinala P, Alho H (2011) Predictors for the efficacy of naltrexone treatment in alcohol dependence: sweet preference. Alcohol Alcohol 46:308–311PubMedGoogle Scholar
  30. Langleben DD, Ruparel K, Elman I, Busch-Winokur S, Pratiwadi R, Loughead J, O'Brien CP, Childress AR (2008) Acute effect of methadone maintenance dose on brain FMRI response to heroin-related cues. Am J Psychiatry 165:390–394PubMedCrossRefGoogle Scholar
  31. Lobmaier P, Kornor H, Kunoe N, Bjorndal A (2008) Sustained-release naltrexone for opioid dependence. Cochrane Database Syst Rev. CD006140Google Scholar
  32. Lobmaier PP, Kunoe N, Gossop M, Katevoll T, Waal H (2010) Naltrexone implants compared to methadone: outcomes six months after prison release. Eur Addict Res 16:139–145PubMedCrossRefGoogle Scholar
  33. McLellan AT, Kushner H, Metzger D, Peters R, Smith I, Grissom G, Pettinati H, Argeriou M (1992) The fifth edition of the Addiction Severity Index. J Subst Abus Treat 9:199–213CrossRefGoogle Scholar
  34. Mihindou C, Vouillac C, Koob GF, Ahmed SH (2011) Preclinical validation of a novel cocaine exposure therapy for relapse prevention. Biol Psychiatry 70(6):593–598PubMedCrossRefGoogle Scholar
  35. Myrick H, Anton RF, Li X, Henderson S, Randall PK, Voronin K (2008) Effect of naltrexone and ondansetron on alcohol cue-induced activation of the ventral striatum in alcohol-dependent people. Arch Gen Psychiatry 65:466–475PubMedCrossRefGoogle Scholar
  36. Nolan LJ, Scagnelli LM (2007) Preference for sweet foods and higher body mass index in patients being treated in long-term methadone maintenance. Subst Use Misuse 42:1555–1566PubMedCrossRefGoogle Scholar
  37. Oslin DW, Berrettini W, Kranzler HR, Pettinati H, Gelernter J, Volpicelli JR, O'Brien CP (2003) A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology 28:1546–1552PubMedCrossRefGoogle Scholar
  38. Paronis CA, Bergman J (2011) Buprenorphine and opioid antagonism, tolerance, and naltrexone-precipitated withdrawal. J Pharmacol Exp Ther 336:488–495PubMedCrossRefGoogle Scholar
  39. Pecina S, Smith KS (2010) Hedonic and motivational roles of opioids in food reward: implications for overeating disorders. Pharmacol Biochem Behav 97:34–46PubMedCrossRefGoogle Scholar
  40. Pecina S, Cagniard B, Berridge KC, Aldridge JW, Zhuang X (2003) Hyperdopaminergic mutant mice have higher “wanting” but not “liking” for sweet rewards. J Neurosci 23:9395–9402PubMedGoogle Scholar
  41. Puigdollers E, Domingo-Salvany A, Brugal MT, Torrens M, Alvaros J, Castillo C, Magri N, Martin S, Vazquez JM (2004) Characteristics of heroin addicts entering methadone maintenance treatment: quality of life and gender. Subst Use Misuse 39:1353–1368PubMedCrossRefGoogle Scholar
  42. Ruan X, Chen T, Gudin J, Couch JP, Chiravuri S (2010) Acute opioid withdrawal precipitated by ingestion of crushed embeda (morphine extended release with sequestered naltrexone): case report and the focused review of the literature. J Opioid Manag 6:300–303PubMedCrossRefGoogle Scholar
  43. Sadava D, Alonso D, Hong H, Pettit-Barrett DP (1997) Effect of methadone addiction on glucose metabolism in rats. Gen Pharmacol 28:27–29PubMedCrossRefGoogle Scholar
  44. Shin AC, Pistell PJ, Phifer CB, Berthoud HR (2010) Reversible suppression of food reward behavior by chronic mu-opioid receptor antagonism in the nucleus accumbens. Neuroscience 170:580–588PubMedCrossRefGoogle Scholar
  45. Smeets PA, de Graaf C, Stafleu A, van Osch MJ, van der Grond J (2005) Functional magnetic resonance imaging of human hypothalamic responses to sweet taste and calories. Am J Clin Nutr 82:1011–1016PubMedGoogle Scholar
  46. Spetter MS, Smeets PA, de Graaf C, Viergever MA (2010) Representation of sweet and salty taste intensity in the brain. Chem Senses 35:831–840PubMedCrossRefGoogle Scholar
  47. Stromberg MF, Meister S, Volpicelli JR, Ulm RR (1997) Morphine enhances selection of both sucrose and ethanol in a two-bottle test. Alcohol 14:55–62PubMedCrossRefGoogle Scholar
  48. Ward AS, Collins ED, Haney M, Foltin RW, Fischman MW (1999) Blockade of cocaine-induced increases in adrenocorticotrophic hormone and cortisol does not attenuate the subjective effects of smoked cocaine in humans. Behav Pharmacol 10(5):523–529Google Scholar
  49. Will MJ, Franzblau EB, Kelley AE (2004) The amygdala is critical for opioid-mediated binge eating of fat. Neuroreport 15:1857–1860PubMedCrossRefGoogle Scholar
  50. Wilson SJ, Sayette MA, Fiez JA (2004) Prefrontal responses to drug cues: a neurocognitive analysis. Nat Neurosci 7:211–214PubMedCrossRefGoogle Scholar
  51. Yu J, Zhang S, Epstein DH, Fang Y, Shi J, Qin H, Yao S, Le Foll B, Lu L (2007) Gender and stimulus difference in cue-induced responses in abstinent heroin users. Pharmacol Biochem Behav 86(3):485–492PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Daniel D. Langleben
    • 1
    • 2
  • Elliot L. Busch
    • 1
  • Charles P. O’Brien
    • 1
  • Igor Elman
    • 3
    • 4
  1. 1.Department of PsychiatryUniversity of Pennsylvania Perelman School of MedicinePhiladelphiaUSA
  2. 2.Philadelphia Veterans Administration Medical CenterPhiladelphiaUSA
  3. 3.Bedford Veterans Administration Medical CenterBedfordUSA
  4. 4.Department of Psychiatry, Cambridge Health AllianceHarvard Medical SchoolBostonUSA

Personalised recommendations